Complete Filing Data
Virax Biolabs Group Ltd reported Cash And Cash Equivalents of $4.23 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Virax Biolabs Group Ltd did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research And Development Expense | $1.8M | $1.6M | $2.2M | $433.7K | $120.2K |
| Profit Loss From Operating Activities | -$6.2M | -$6.5M | -$5.7M | -$1.7M | -$644.5K |
| Profit Loss Before Tax | -$6.2M | -$6.7M | -$5.5M | -$1.7M | -$672.9K |
| Profit Loss Attributable To Owners Of Parent | -$6.1M | -$6.7M | -$5.5M | -$1.7M | -$651.0K |
| Profit Loss Attributable To Noncontrolling Interests | -$6.0K | -$5.6K | -$269.00 | -$41.0K | -$21.9K |
| Profit Loss | -$6.1M | -$6.7M | -$5.5M | -$1.7M | -$672.9K |
| Other Comprehensive Income Net Of Tax Exchange Differences On Translation | $110.4K | $3.6K | $111.00 | $1.0K | -$3.9K |
| Interest Revenue Expense | $58.2K | -$26.9K | -$15.5K | -$15.4K | -$28.6K |
| General And Administrative Expense | $4.3M | $4.6M | $3.6M | $1.3M | $457.7K |
| Comprehensive Income Attributable To Owners Of Parent | -$6.0M | -$6.7M | -$5.5M | -$1.7M | -$646.4K |
| Comprehensive Income Attributable To Noncontrolling Interests | -$6.0K | -$5.6K | -$269.00 | -$78.1K | -$30.2K |
| Comprehensive Income | -$6.0M | -$6.7M | -$5.5M | -$1.7M | -$676.6K |
| Revenue From Contracts With Customers | $6.3K | $156.4K | $8.6K | $0.00 | $123.8K |
| Other Comprehensive Income Net Of Tax Exchange Differences On Translation Attributable To Owners Of Parent | -$3.6K | -$111.00 | -$965.00 | $3.7K | |
| Gross Profit | -$53.1K | $50.6K | -$1.4K | -$9.4K | |
| Cost Of Sales | $59.4K | $105.8K | $9.9K | $133.3K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash And Cash Equivalents | $4.2M | $3.6M | $9.4M | $21.8K | $17.6K | $22.6K |
| Cash Flows From Used In Operating Activities | -$4.6M | -$6.2M | -$4.2M | -$809.1K | -$590.2K | |
| Cash Flows From Used In Financing Activities | $5.8M | $1.6M | $13.7M | $813.2K | $585.2K | |
| Cash Advances And Loans From Related Parties | -$18.3K | -$111.6K | $193.6K | $182.0K | ||
| Adjustments For Increase Decrease In Trade Account Payable | $129.3K | -$572.2K | $33.9K | $641.2K | $81.6K | |
| Retained Earnings | -$24.6M | -$18.5M | -$11.8M | -$6.3M | -$4.6M | |
| Liabilities | $964.8K | $345.2K | $908.4K | $1.2M | $871.4K | |
| Issue Of Equity | $5.1M | $13.7M | $519.6K | $403.2K | ||
| Equity Attributable To Owners Of Parent | $5.7M | $5.4M | $9.1M | -$974.6K | -$650.7K | |
| Equity And Liabilities | $6.4M | $5.5M | $9.8M | $48.7K | $39.6K | |
| Current Liabilities | $673.2K | $168.8K | $908.4K | $1.2M | $871.4K | |
| Current Assets | $4.9M | $4.4M | $9.6M | $48.7K | $39.6K | |
| Current Accounts Payable And Accrued Liabilities | $250.2K | $120.9K | $705.6K | $1.1M | $496.6K | |
| Assets | $6.4M | $5.5M | $9.8M | $48.7K | $39.6K | |
| Adjustments For Gain On Debt Extinguishment | $12.5K | $294.4K | $5.6K | |||
| Accumulated Other Comprehensive Income | $112.3K | $2.0K | -$1.7K | -$1.8K | -$2.8K | |
| Issue Of Equity For Settlement Of Related Party Payable | $39.9K | $452.9K | $604.9K | |||
| Trade And Other Current Payables To Related Parties | $337.6K | $18.3K | $126.2K | $371.1K | ||
| Issue Of Equity For Services | $20.0K | $290.4K | ||||
| Cash Flows From Used In Investing Activities | -$603.9K | -$1.2M | -$178.4K | |||
| Payments On Note Payable | $149.9K | $341.3K | ||||
| Adjustments For Increase Decrease In Deferred Income Other Than Contract Liabilities | -$38.3K | $38.3K | ||||
| Adjustments For Decrease Increase In Trade Account Receivable | $337.6K | $928.00 | -$928.00 | |||
| Noncurrent Assets | $1.5M | $1.1M | $178.4K | |||
| Current Value Added Tax Receivables | $30.7K | $217.8K | $0.00 | |||
| Stock Issued During Period Value Cashless Warrant Exercise | $9.00 | |||||
| Rightofuse Assets | $306.7K | $206.1K | ||||
| Purchase Of Property Plant And Equipment Classified As Investing Activities | $603.9K | $952.5K | ||||
| Property Plant And Equipment | $1.2M | $897.6K |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Proceeds From Issuing Shares | 5.1M | 234.00 | 13.7M | 519.6K | 403.2K |
| Increase Decrease In Cash And Cash Equivalents | $639.7K | -$5.8M | $9.3M | $4.1K | -$5.0K |
| Proceeds From Note Payable | $487.5K | $100.0K | |||
| Proceeds From Exercise Of Warrants | $786.7K | $1.9M |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Number Of Shares Issued | 4.3M | 2.6M | 1.6M | 10.0M | 103.0M | |
| Weighted Average Shares | 3.7M | 2.0M | 1.1M | 956.3K | ||
| Par Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | ||
| Number Of Shares Outstanding | 4.3M | 2.6M | 1.6M | 10.0M | 103.0M | 20.00 |
| Diluted Earnings Loss Per Share | $-1.62 | $-3.36 | $-5.13 | $-1.79 | ||
| Basic Earnings Loss Per Share | $-1.62 | $-3.36 | $-5.13 | $-1.79 | ||
| Adjusted Weighted Average Shares | 3.7M | 2.0M | 1.1M | 956.3K | ||
| Shares Issued For Settlement Of Related Party Payable | 149.4K | 452.9K | 25.0K | |||
| Shares Issued For Conversion Of Convertible Debt | 100.0K |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Other Income Expenses | -$41.0K | -$242.6K | $275.0K | -$16.2K | -$28.4K |
| Other Income Expense Net | -$17.2K | -$215.8K | $290.5K | -$753.00 | $266.00 |
| Operating Expense | $6.1M | $6.5M | $5.7M | $1.7M | $635.1K |
| Adjustments For Unrealised Foreign Exchange Losses Gains | $123.7K | $3.7K | $111.00 | $5.7K | -$3.9K |
| Adjustments For Decrease Increase In Inventories | -$34.3K | -$60.4K | $21.0K | $121.00 | -$21.1K |
| Adjustments For Decrease Increase In Prepaid Expenses | -$26.6K | -$231.3K | -$275.5K | $2.2K | |
| Noncontrolling Interests | -$234.0K | -$228.0K | -$222.4K | -$222.1K | -$181.1K |
| Capital Reserve | $30.2M | $23.9M | $20.9M | $5.4M | $4.0M |
| Number Of Shares Authorised | 50.0M | 50.0M | 50.0M | 492.0M | |
| Inventories | $94.7K | $60.4K | $0.00 | $21.0K | $21.1K |
| Current Prepaid Expenses And Deposits | $539.4K | $512.8K | $281.5K | $6.0K | |
| Adjustments For Sharebased Payments | $365.3K | $1.0M | $1.7M | $290.4K | |
| Issued Capital | $4.3K | $2.6K | $1.6K | $999.00 | |
| Interest Paid Classified As Operating Activities | -$79.0K | $6.1K | $15.5K | ||
| Employee Benefits Expense | $365.3K | $1.0M | $1.7M | ||
| Stock Issued For Services | $20.0K | $290.4K | |||
| Stock Issued During Period Value Pre Funded Warrant Exercise | $234.00 | $117.00 | |||
| Selling Expense | $26.6K | $13.8K | $57.2K | ||
| Purchase Of Internally Developed Software Classified As Investing Activities | $212.0K | $178.4K | |||
| Increase Decrease Through Transfer To Statutory Reserve | $21.1K | $27.0K |
Most recent annual filing with the SEC: July 2, 2025
Data sourced from SEC EDGAR public filings as of August 7, 2026.